Epilepsy | Unmet Need | Lennox Gastaut Syndrome | US/EU | 2016

Lennox-Gastaut syndrome (LGS) is a severe, pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities. LGS patients have a higher mortality rate than age-matched peers, with seizure complications being a prominent contributing factor. Despite the availability of more than 25 antiepileptic drugs (AEDs), several of which are approved specifically to treat LGS, the majority of LGS patients do not attain adequate seizure control even with chronic polypharmacy. Despite the highly genericized nature of the epilepsy market, opportunity exists for novel branded therapies that offer greater efficacy, safety, and tolerability than approved or commonly prescribed LGS treatment options.

Login to access report

launch Related Market Assessment Reports